Literature DB >> 26989028

Metabolic Syndrome and Deep Vein Thrombosis After Total Knee and Hip Arthroplasty.

Kai Song1, Zhen Rong2, Yao Yao2, Yeshuai Shen2, Minghao Zheng3, Qing Jiang2.   

Abstract

BACKGROUND: Metabolic syndrome (MS), defined as obesity, hypertension, hyperglycemia, and dyslipidemia, is prevalent among patients undergoing total joint arthroplasty (TJA). MS has proven to promote a proinflammatory and prothrombotic state in patients. Venous thromboembolism is one of the major complications of TJA. The purpose of this retrospective study is to identify whether MS and its components increase the risk of deep vein thrombosis (DVT) after TJA.
METHODS: We retrospectively reviewed 1553 patients undergoing primary unilateral TJA from 2007 to 2014. MS was diagnosed based on the World Health Organization criteria. All subjects received venography after operation to screen for DVT. Symptomatic DVT events after TJA were also recorded. Univariate analysis and multivariate logistic regression analysis were used to identify the association of MS and its components with postoperative DVT.
RESULTS: The prevalence of MS in patients undergoing TJA was 5.1% (n = 79). A total of 335 patients (21.6%) were diagnosed with DVT by venography. Seventy-eight patients (5.0%) developed symptomatic DVT. In the total knee arthroplasty group, MS and obesity were related to postoperative DVT. MS alone was found to be associated with symptomatic DVT. In the total hip arthroplasty group, MS increased the risk of symptomatic DVT. However, obesity, rather than MS, was associated with total DVT after total hip arthroplasty.
CONCLUSIONS: MS was a significant risk factor for DVT after TJA. Strategies to minimize the adverse effect of MS should be considered for these patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  deep vein thrombosis; metabolic syndrome; total hip arthroplasty; total knee arthroplasty; venography

Mesh:

Year:  2015        PMID: 26989028     DOI: 10.1016/j.arth.2015.12.021

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  7 in total

1.  Does metabolic syndrome predict surgical complications? A protocol for a systematic review and meta-analysis.

Authors:  Philip Norris; Nicholas Ralph; Clint Moloney
Journal:  Syst Rev       Date:  2017-06-17

2.  Acupuncture for perioperative care of total hip arthroplasty: A systemic review of controlled trials and meta-analysis.

Authors:  Hee-Ra Shin; Kyungtae Park; Jihye Seo; Sung-Hu An; Seung-Ryong Yeom; Young-Dal Kwon
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

Review 3.  Patients with metabolic syndrome have a greater rate of complications after arthroplasty: A systematic review and meta-analysis.

Authors:  Cui Guofeng; Yue Chen; Wei Rong; Liu Ruiyu; Wang Kunzheng
Journal:  Bone Joint Res       Date:  2020-05-16       Impact factor: 5.853

4.  Association between metabolic syndrome and venous thromboembolism after total joint arthroplasty: a meta-analysis of cohort studies.

Authors:  Yipei Yang; Ziyue Li; Haifeng Liang; Jing Tian
Journal:  J Orthop Surg Res       Date:  2020-11-30       Impact factor: 2.359

5.  The application of Caprini Risk Assessment Model in evaluation of deep vein thrombosis for patients with end-stage osteoarthritis before arthroplasty.

Authors:  Wei Sun; Dongmei Ai; Yao Yao; Kewei Ren; Jun Lu; Huiqing Sun; Xiaotao Wu; Qing Jiang
Journal:  BMC Musculoskelet Disord       Date:  2022-08-12       Impact factor: 2.562

6.  Association between hyperglycemia on admission and preoperative deep venous thrombosis in patients with femoral neck fractures.

Authors:  Qiaomei Lv; Wenbo Ding; Wei Yao; Wanyun Tang; Wei Wang
Journal:  BMC Musculoskelet Disord       Date:  2022-10-06       Impact factor: 2.562

7.  Incidence and risk factors of deep venous thrombosis following arthroscopic posterior cruciate ligament reconstruction.

Authors:  Dongyang Chen; Qiangqiang Li; Zhen Rong; Yao Yao; Zhihong Xu; Dongquan Shi; Qing Jiang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.